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Received 9 April 2017; revised 27 May 2017; accepted 1 June 2017AbstractThis article reviews the effectiveness of intratympanic corticosteroids for vertigo control in Meniere's disease at 2-years follow-up according
to the guidelines expressed by the American Academy of Otolaryngology-Head & Neck Surgery. Despite the increased use of intratympanic
corticosteroids for vertigo control in Meniere's disease there is debate as to their effectiveness, particularly compared to gentamicin. Even so,
after just a single course of injections, corticosteroids can reliably provide complete vertigo control (Class A) at 2-years in about 50% of cases as
indicated in a recent double-blind randomized controlled clinical trial (Patel et al., 2016). But the effectiveness of intratympanic corticosteroids
truly increases when treatment is provided ‘as-needed’, whereby complete vertigo control is established in up to 91% of cases. On the basis of
available literature, there is good evidence to recommend the use of intratympanic steroid treatment for vertigo control in Meniere's disease, but
patients must be monitored for non-response. The rationale for treating patients as-needed and the possible reasons for corticosteroid non-
response are discussed.
Copyright © 2017, PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Meniere's disease is associated with unstable or fluctuating
levels of hearing and vestibular function from a failure of one
or more of the inner ear mechanisms regulating endolymph
and perilymph, afferent and efferent nerve signaling,
intercellular signaling, metabolism and blood flow (Rauch,
2016). Consequently, hearing and balance functions becomeniere's disease: A mini-review, Journal of Otology (2017), http://dx.doi.org/
gy Head and Neck Surgery. Production and hosting by Elsevier (Singapore)
eativecommons.org/licenses/by-nc-nd/4.0/).
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stress, poor diet, hormonal variations, and barometric pressure
changes (Rauch, 2010).
The active periods of Meniere's disease tend to occur in
clusters of 6e11 per year, although remission may last several
months or years (Phillips and Westerberg, 2011). The char-
acteristics of Meniere's disease are well documented: episodic
attacks of vertigo, a fluctuating and progressive hearing loss,
tinnitus and aural fullness, but the most disabling feature is
vertigo (S€oderman et al., 2002). Episodes of vertigo tend to
occur with higher frequency in the first few years after pre-
sentation and then decrease (Moffat, 1997).
Clinically, episodic vertigo can be quelled or reduced
through intratympanic therapy (Sajjadi and Paparella, 2008)
which involves the injection of either gentamicin or (cortico)
steroid through the tympanic membrane into the middle ear
space. The drug is absorbed into the inner ear perilymph pri-
marily through the semi-permeable round window membrane,
but also via the oval window annular ligament and the small
lacunar mesh surrounding the inner ear (Phillips and
Westerberg, 2011). The delivery of intratympanic gentamicin
in Meniere's disease has been proven to quell the frequency
and severity of vertigo attacks (Pullens and van Benthem,
2011), but, since the effect relies on ototoxic properties, pa-
tients are left with a permanent vestibular deficit and about
20% of patients experience hearing loss. Poor compensation
from the acute vestibular loss can also result in persistent
disequilibrium and postural unsteadiness. Corticosteroid,
which does not ablate inner ear function, is sometimes used as
a substitute to gentamicin in Meniere's disease (Itoh and
Sakata, 1991; Sakata et al., 1986), but its efficacy has been
contested (for review see (Lavigne et al., 2016)). Steroids
would be preferred by many patients because they have no
side-effects and unlike gentamicin are suitable in bilateral
disease - but their effects can be short-lived (Atrache Al
Attrache et al., 2016), injections can be painful and a posi-
tive response depends upon an inflammatory etiology
(McCabe, 1979). However, evidence supporting the use of
steroids in Meniere's disease include increased immune com-
plexes (Brookes, 1986), complement (Xenellis et al., 1986),
positive response to antigens (Suzuki et al., 1997), local
inflammation and vascular events (Espinosa-Sanchez and
Lopez-Escamez, 2016) and a higher prevalence of autoim-
mune symptoms (Gazquez et al., 2011) in Meniere's disease
patients over controls.average number of attacks per month in the final six months of treatment
average number of vertigo attacks per month for the six months before treatment
 100Compared to systemic steroid administration, intra-
tympanic steroid results in 260 higher levels of steroid in
the perilymph (Bird et al., 2011) as it bypasses thePlease cite this article in press as: Patel, M., Intratympanic corticosteroids in Me
10.1016/j.joto.2017.06.002blood labyrinthine barrier. Although the action of steroids on
the inner ear remains speculative, it may involve anti-
inflammatory effects, immunosuppression and/or ion ho-
meostasis (Hamid and Trune, 2008) as glucocorticoid re-
ceptors are present in vast numbers in the vestibular and
cochlear systems. Via these receptors, steroids affect thou-
sands of genes (Fukushima et al., 2002) and influence aqua-
porins (Fukushima et al., 2002; Pondugula et al., 2004), a
family of small trans-membrane water transporters which
play a role in regulating inner ear fluids, blood flow
(Shirwany et al., 1998) and the endocochlear potential
(Hamid and Trune, 2008).
Given the ongoing debate as to intratympanic steroid use in
Meniere's disease (Dodson et al., 2004; Doyle et al., 2004;
Gabra and Saliba, 2013; Silverstein et al., 1998), herewith, I
review published results on the effectiveness of intratympanic
steroids in Meniere's disease for vertigo control. Only studies
meeting 2-years follow-up are considered.
2. Methods
In March 2017, PubMed was searched for English-
language studies with the terms “Meniere's disease”, “ste-
roid”, “corticosteroid”, “methylprednisolone”, “dexametha-
sone” and “intratympanic”, meeting the criteria for definite
Meniere's disease according to guidelines recommended by
the American Academy of Otorhinolaryngology-Head and
Neck Surgery and evaluation of treatment for at least 2-years
(AAO-HNS, 1995). Definite Meniere's disease was two or
more episodes of vertigo lasting 20-min or longer, significant
unilateral sensorineural hearing loss, and either tinnitus or
aural fullness after ruling out other otological or central con-
ditions. Patients were unresponsive to conventional treatment
(i.e., dietary/oral) for at least six months previous. Studies
were not restricted to randomized controlled trials, blinded
studies or unilaterality. However, only studies using the
American Academy of Otorhinolaryngology-Head and Neck
Surgery guidelines for reporting vertigo control (1995) at 2-
years were considered.
The primary outcome measure was the percentage of pa-
tients with Class Avertigo control where the number of attacks
of vertigo are categorized into Classes AeF: Complete Con-
trol (A), Substantial Control (B), Limited Control (C), Insig-
nificant Control (D), Worse Control (E) and Secondary
treatment required (F) with the following formula:where, 0 ¼ Complete Control, 1e40 ¼ Substantial Control,
41e80 Limited Control, 81e120 Insignificant Control and
>120 Worse Control of vertigo. Studies in which results areniere's disease: A mini-review, Journal of Otology (2017), http://dx.doi.org/
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marked as such.
3. Results
Twelve studies fulfilled inclusion criteria. As shown in
Table 1, the median percentage of patients with complete
(Class A) control after intratympanic steroids at 2-years was
71.7 (IQR 42.5e81.0%). Eight studies used an ‘as-needed’
protocol, but the number of injections for one course and drug
concentration varied considerably. An as-needed protocol
tended to be more beneficial than single-treatment, but figures
for vertigo control varied. A brief description of each study is
given below.3.1. Barrs, 2004In a retrospective study of 34 Meniere's disease patients
after 4 consecutive weekly injections of dexamethasone,
complete vertigo control was achieved at 2-years in 8/34 pa-
tients (24%). Eighteen patients (53%) had no control of ver-
tigo, as deemed by a relapse of vertigo or switching to
intratympanic gentamicin treatment after relapse. One patient
experienced an improvement in hearing after dexamethasone,
scoring better in speech discrimination than before treatment
but there were no mean changes for hearing. Two patients
experienced tympanic perforation after injection.3.2. Garduno-Anaya et al., 2005Garduno-Anaya and colleagues compared intratympanic
dexamethasone (n ¼ 11) to placebo (n ¼ 11) over 2-years. TheTable 1
Summary of studies meeting inclusion criteria on the effectiveness of intratympanic
control was used as the primary outcome in this Review.
Study Steroid type Conc.
(mg/ml)
Treatment protocol
Barrs, 2004 Dex 10 1 injection for 4 consecutiv
Garduno-Anaya et al., 2005 Dex 4 1 injection daily for 5 cons
Boleas-Aguirre et al., 2008 Dex 12 1 injection
Herraiz et al., 2010 Methylpred 40 1 injection for 3 consecutiv
Casani et al., 2012 Dex 4 1 injection over 3 consecut
Martin-Sanz et al., 2013a Dex 4 1 injection weekly for 3 co
Martin-Sanz et al., 2013b Dex 4 1 injection daily for 3 cons
1 injection for 3 consecutiv
McRackan et al., 2014 Dex 24 1 injection, 3 doses deliver
She et al., 2015 Methylpred 20 1 injection over 10 consecu
Albu et al., 2016 Dex 4 1 injection over 3 consecut
1 injection over 3 consecut
days þ high-dose betahistin
Patel et al., 2016 Methylpred 62.5 1 injection fortnightly (1 co
Leng et al., 2017 Dex 5 1 injection for 4 consecutiv
over 4 consecutive weeks
Dex ¼ Dexamethasone; Methylpred ¼ Methylprednisolone.
a No further treatments were needed or asked for.
b Vertigo control outcome was customized (Class A þ Class B control), but the
Please cite this article in press as: Patel, M., Intratympanic corticosteroids in Me
10.1016/j.joto.2017.06.002treatment protocol was one injection for five days at baseline.
There was a significant improvement in complete vertigo
control (dexamethasone: 82% vs. placebo: 57% achieving
Class A), subjective functional level (90 vs. 42% achieving
Level 1) and drop in dizziness handicap inventory scores (60.4
vs. 41.3 points) in the dexamethasone group over placebo. No
patient in the dexamethasone group was deemed a treatment
failure, whereas 5/11 patients were deemed failures in the
placebo group. There was an improvement in subjective
hearing in the dexamethasone group over controls (100% vs.
35%) but no difference for objective hearing measured with
pure-tone audiometry or speech discrimination. Although
there was a subjective improvement in tinnitus (48%) and
aural fullness (48%) in the dexamethasone group, there was no
difference between groups for tinnitus handicap inventory
scores or grading of tinnitus severity.3.3. Boleas-Aguirre et al., 2008In a retrospective study of intratympanic dexamethasone
delivered as-needed in 129 Meniere's disease patients over 2-
years, vertigo control (meaning no further treatments
were needed or asked for) was achieved in 117/129 (91%)
patients. A single injection of dexamethasone was required
in 48 cases (37%), two injections in 26 cases (20%), three
injections in 18 cases (14%), four injections in 15 cases
(21%) and more than four injections in 15 cases (21%).
Twelve patients were dissatisfied and opted for intra-
tympanic gentamicin treatment. Of these 12 failures, 9
switched to gentamicin within the first 6-months after
baseline treatment. Hearing was unchanged after intra-
tympanic dexamethasone.steroid injections in Meniere's disease over 2-years. Class A (complete) vertigo
Further
injections
offered
‘as-needed’
Study type Sample
size for
steroid
arm
Percentage of
patients with
Class A vertigo
control (%)
e weeks Yes Retrospective 34 24
ecutive days No Prospective 11 82
Yes Retrospective 129 91a
e days Yes Prospective 29 78
ive days Yes Prospective 28 43
nsecutive weeks No Prospective 53 15.1
ecutive days or
e weeks
No Retrospective 22/34 40.9/44.1
ed 10 min s apart Yes Retrospective 159 81.1b
tive days No Retrospective 16 81
ive days or
ive
e
Yes Prospective 32/30 44/73.3
urse ¼ 2 injections) Yes Prospective 30 70
e days, Yes Retrospective 23 73.9
study was of sufficient quality to merit inclusion.
niere's disease: A mini-review, Journal of Otology (2017), http://dx.doi.org/
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29 Meniere's disease patients was studied prospectively after 3
consecutive daily injections at baseline and thereafter as-
needed. Seventy-eight percent of cases (22/29) were free of
vertigo (Class A vertigo control), and 96% had none or 1 spell
at 2-years. Because of relapsing vertigo, 12 patients (35.2%)
required re-treatment over the 2-year period. Two patients
(6.25%) required intratympanic gentamicin after experiencing
no vertigo control (at 14 and 18-months). There was no overall
effect of methylprednisolone on hearing but tinnitus relief was
achieved in 78% of the patients. Two patients experienced
tympanic perforation after injection. Burning and pain after
injection were minimal and lasted no more than 2-h.3.5. Casani et al., 2012In an open-label, randomized trial comparing intratympanic
dexamethasone (n ¼ 28) to gentamicin (n ¼ 32) over 2-years,
Casani and colleagues treated unilateral Meniere's disease
patients with 3 injections over consecutive days (one course).
Thereafter, patients with relapsing vertigo were offered further
intratympanic treatment (i.e., as-needed). The authors found
that complete vertigo control (Class A) after intratympanic
dexamethasone was achieved in 12/28 patients (43%) and
good control in 5 patients (18%) at 2-years. Four dexameth-
asone patients received two courses (14.3%) and 5 dexa-
methasone patients received three courses (17.9%). Two
dexamethasone patients experienced no vertigo control and
were switched to intratympanic gentamicin. Gentamicin
established complete vertigo control in 26/32 (81%) of cases.
There were no changes to pure-tone hearing or speech
discrimination after intratympanic dexamethasone, but there
was a significant loss in speech discrimination in the genta-
micin group.3.6. Martin-Sanz et al., 2013a,bMartin-Sanz conducted a prospective study on the effec-
tiveness of one intratympanic dexamethasone injection deliv-
ered for three consecutive weeks at baseline in 53 Meniere's
disease patients. At 2-years, complete control (Class A) was
achieved in 15.1% and an overall level of good control (Class
A þ B) in 32.1% (Martin-Sanz et al., 2013a). However, a
retrospective study of patients by the same authors after 1
dexamethasone injection for 3 consecutive days (n ¼ 22) or 1
dexamethasone injection for 3 consecutive weeks (n ¼ 34)
showed complete control at 2-years in 40.9 and 44.1%
respectively (Martin Sanz et al., 2013b).3.7. McRackan et al., 2014McRackan and colleagues conducted a ten-year retrospec-
tive study of 159 Meniere's disease patients treated with
intratympanic dexamethasone after 3-perfusions, 10-min
apart, at baseline and then delivered as-needed i.e., ifPlease cite this article in press as: Patel, M., Intratympanic corticosteroids in Me
10.1016/j.joto.2017.06.002symptoms worsened or persisted patients were re-treated.
Overall, 129/159 patients (81.1%) experienced complete or
good vertigo control (Classes A þ B) at 2-years follow-up.
Most symptoms were abated with five or fewer treatments
(73.6%) and for each treatment there was a 20% decrease in
the likelihood of further treatment. Only one treatment was
needed in 24.5% of patients. One patient required tympano-
plasty following tympanic membrane perforation. The
outcome measure in this study did not distinguish between
Class A and Class B control, but because there is sufficient
clarity and quality, the study has been included in this Review.3.8. She et al., 2015She and colleagues conducted a 2-year retrospective anal-
ysis of 16 Meniere's disease patients after intratympanic
methylprednisolone delivered once daily for 10 consecutive
days at baseline (10 injections). Complete vertigo control
(Class A) was achieved at 2-years in 13/16 (81%) cases. Two
patients continued to experience severe vertigo episodes and
switched to intratympanic gentamicin treatment at 12 and 18-
months. One patient experienced tympanic membrane perfo-
ration four years after treatment but there were no other
adverse events. There was no significant change in hearing
after intratympanic methylprednisolone and 2/16 patients
(12%) experienced a reduction in tinnitus. No patient experi-
enced a worsening of tinnitus. Functional activity scores
improved after treatment by 87% over 2-years.3.9. Albu et al., 2016In a comparative effectiveness study between intratympanic
dexamethasone delivered once on three consecutive days and
intratympanic dexamethasone with daily high dose betahistine
(144 mg/day), complete vertigo control (Class A) for the
steroid only group was achieved in 14/32 (44%) patients
whereas combined steroid and betahistine therapy achieved
complete vertigo control in 22/30 (73.3%) at 2-years. Sub-
stantial vertigo control or better (Class A þ B) was indicated
in 21/32 patients (65.6%) in the single therapy group and in
27/30 patients (90%) in the combined therapy group. In-
jections were repeated as-needed. In the intratympanic steroid
group, 5 patients received one additional injection (15%) and 6
patients (18%) received two additional injections. In the
combined intratympanic steroid and betahistine group, 4 pa-
tients received one additional injection (12%) and 3 patients
received two additional injections (10%). One patient from
both groups experienced no control of vertigo and both were
subsequently scheduled for intratympanic gentamicin. Hearing
and tinnitus were unchanged. Functional level scores
mimicked the level of vertigo control.3.10. Patel et al., 2016Intratympanic methylprednisolone (n ¼ 30) was compared
to intratympanic gentamicin (n ¼ 30) in a double-blind,
controlled, randomized comparative effectiveness study overniere's disease: A mini-review, Journal of Otology (2017), http://dx.doi.org/
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baseline with two injections and thereafter further courses
were given as-needed. In the methylprednisolone group,
complete vertigo control (Class A) was achieved in 21/30
patients (70%) compared to 25/30 (83.3%) in the gentamicin
group. After methylprednisolone, 22 patients (78.5%) experi-
enced an improved Functional Level score and 8 patients
(28.7%) better pure-tone hearing and speech discrimination.
There were also reductions for tinnitus, dizziness and aural
fullness. Fifteen patients (50%) required further courses of
methylprednisolone. Two patients were deemed treatment
failures and were assigned intratympanic gentamicin treat-
ment. The study showed no significant difference between the
methylprednisolone and gentamicin for the control of vertigo,
total number of injections, number of patients with relapsing
vertigo or for the amount of pain from injection but better
speech discrimination after methylprednisolone. Two patients
in the methylprednisolone group experienced post-injection
ear infections.3.11. Leng et al., 2017Leng and colleagues conducted a retrospective study of
intratympanic dexamethasone in 51 MD patients delivered at
baseline and then as-needed. One complete course was four
injections administered on a weekly basis for 4 consecutive
weeks (16 injections). Twenty-three Meniere's disease patients
were followed-up for at least 2-years (24e77 months). At 2-
years, 17/23 (73.9%) achieved complete vertigo control
(Class A). Eleven patients (21%) required re-treatment and
three patients failed to respond to intratympanic dexametha-
sone. Hearing was unchanged but there was a dramatic
improvement in Functional Level scores (from mean 5 to 2).
4. Discussion
Although poorly understood, inflammatory and autoim-
mune processes appear to be linked to the development of
Meniere's disease (Gazquez et al., 2011; Greco et al., 2012;
Riente et al., 2004). Support for this is the successful reduc-
tion of vertigo and hearing symptoms after steroid treatment.
However, for a subset of patients, steroid offers no relief and
this has led to debate as to its overall effectiveness. Results
here (see Table 1) support the use of intratympanic steroid for
vertigo control in Meniere's disease, especially when delivered
as-needed (median 71.7% complete control). Moreover, ste-
roid injections as-needed seem to be equally effective to
gentamicin for vertigo control in unilateral Meniere's disease
(Patel et al., 2016; Sennaroglu et al., 1999), but because ste-
roid is non-ablative, it could be considered first-choice for
many patients.
Due to the fluctuating nature of symptoms and poor un-
derstanding of disease etiology, treatment of Meniere's disease
is challenging. This is further complicated by data showing
that vertigo resolves in 57% of patients after 2-years and 71%
after 8-years with the disease (Silverstein et al., 1989).
Moreover, as bilateral involvement increases with diseasePlease cite this article in press as: Patel, M., Intratympanic corticosteroids in Me
10.1016/j.joto.2017.06.002progression, ablative treatment must be given with caution.
However, until recently, only ablative treatment had been
proven to achieve significant vertigo control under strict sci-
entific conditions. A randomized double-blind clinical trial has
now shown that intratympanic steroid can fulfill this require-
ment especially when patients are treated as-needed (Patel
et al., 2016), a result that is supported by other non-
controlled studies (e.g., Boleas-Aguirre et al., 2008;
McRackan et al., 2014). This finding is particularly welcome
because intratympanic steroid carries few adverse effects and
Cochrane Reviews have found insufficient evidence to support
the use of betahistine (James and Burton, 2001), diuretics
(Thirlwall and Kundu, 2006), positive pressure treatment (van
Sonsbeek et al., 2015) or endolymphatic sac surgery (Pullens
et al., 2013). The below discusses the rationale for treating
patients with intratympanic steroid as-needed and the possible
reasons for non-response.
As can be seen in Table 1, the reported success of intra-
tympanic steroid for vertigo control in Meniere's disease varies
widely, presumably because the benefits of steroid are tem-
porary and relatively short-lived (Miller and Agrawal, 2014).
Crucially, patients with an autoimmune variant of the disease
are likely to respond better to steroid treatment. Remarkably,
this subgroup of Meniere's disease patients is one of five
identified (Frejo et al., 2016, 2017). Despite this, one course of
intratympanic steroid quells vertigo episodes over 2-years in
about 25e50% of patients (Barrs, 2004; McRackan et al.,
2014; Patel et al., 2016). However, in some patients, intra-
tympanic steroid treatment must be repeated but the response
to treatment seems to improve with each further injection
(McRackan et al., 2014) and may provide complete control of
vertigo in up to 91% of cases at 2-years. Rather than a one-off
treatment like intratympanic gentamicin, intratympanic steroid
appears to be more effective delivered as-needed.
Reasons for having to repeat steroid injections could include
low steroid concentration or lower overall cumulative dosage.
Indeed, there seems to be a trend between higher steroid con-
centration or dosing and the percentage of patients with com-
plete vertigo control, a finding that has been pointed out
previously (Albu et al., 2015). One of the best results was shown
by Hamid (Hamid and Trune, 2008), who after treating patients
with 24 mg/ml dexamethasone, found complete vertigo control
and hearing improvement in 90% of Meniere's patients at 2-
years, with no significant side-effects. Similarly, Shea and Ge
(Shea and Ge, 1996) delivered dexamethasone in a combination
of intratympanic, intravenous and oral forms in 28 Meniere's
disease patients which established complete vertigo control in
63% of patients, reduced dizziness in 96.4% and improved
hearing in 35%. Although these results support the conclusion
that a high dose of steroid is effective, the optimal treatment
protocol is yet to be properly established. This is a challenging
task because there is considerable variation in symptoms across
patients and over time, but more concerning is the subset of
patients who do not respond to treatment at all. With numerous
homeostatic mechanisms required for normal ear function
(Trune and Canlon, 2012) and five disease subtypes (Frejo et al.,
2016, 2017), it is not so surprising that steroid does not work forniere's disease: A mini-review, Journal of Otology (2017), http://dx.doi.org/
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ear linked to the production of hydrops (Salt and Plontke, 2010)
are influenced by steroids other than glucocorticoids (Trune,
2010), indicating a self-limiting sensitivity to corticosteroid
treatment. Another consideration is that about 25e35% of
migrainers experience episodic attacks of vertigo (Kayan and
Hood, 1984) and sensorineural hearing loss (Lee et al., 2000),
which could cloud the diagnosis of Meniere's disease. Further-
more, the prevalence of migrainous vertigo in Meniere's disease
is as high as 31% (Wladislavosky-Waserman et al., 1984; Shin
et al., 2013), which may bias a patient's assessment of disease-
related vertigo attacks.
The need for further injections would normally be consid-
ered a drug failure under the American Academy's criteria
(AAO-HNS, 1995), but as steroid treatment is accepted to be
short-lasting, these criteria have to be adjusted. The results of
recent studies in Meniere's disease have accommodated for this
problem by stating the number of re-injections, number of
patients changing treatment (failures) and the class of vertigo
control without regard to re-treatment. In the case of intra-
tympanic steroid, the reasons to continue with treatment may
include reduction in the frequency or severity of vertigo at-
tacks, reduced aural fullness or tinnitus, risk of hearing loss or
disequilibrium from other therapies or bilateral involvement.
Repeated injections of steroid may seem disadvantageous due
to the burden of possible relapse, especially compared to
intratympanic gentamicin (Boleas-Aguirre et al., 2008). How-
ever, a significant proportion (22%) of patients treated with
intratympanic gentamicin require further injections to control
vertigo (Minor, 1999), and in a double-blind randomized
controlled trial comparing intratympanic steroid to gentamicin,
the number of patients requiring further injections and the
overall number of injections was not significantly different
between treatment groups (Patel et al., 2016). A second
consideration is the type of steroid. Methylprednisolone is
considered superior to dexamethasone as peak concentrations
are higher and remain within the perilymph for longer (Parnes
et al., 1999). But data in this Review suggest that both meth-
ylprednisolone and dexamethasone are equally effective.
This Review has limitations. The main focus of this Review
was the percentage of patients with Class A vertigo control.
Although Class B vertigo control may be adequate to some
patients, it may still be very debilitating for others. Hearing
outcomes were not addressed in this Review, but no study
showed a significant drop in hearing after steroid.
The beneficial effects of steroid treatment in Meniere's dis-
ease were not limited to studies meeting inclusion criteria for
this Review. Various studies did not meet the full 2-years
follow-up (Hirvonen et al., 2000; Paragache et al., 2005; Ren
et al., 2015) or the AAO-HNS guidelines for reporting vertigo
control (AAO-HNS, 1995) but showed successful control of
vertigo after intratympanic steroid . An example is a recent
study by Atrache Al Attrache et al. (2016), which showed a
dramatic reduction in the number of vertigo spells after intra-
tympanic dexamethasone over 2-years. Furthermore, in a
particularly elegant study, steroid treatment alongside endo-
lymphatic sac shunting established complete control of vertigoPlease cite this article in press as: Patel, M., Intratympanic corticosteroids in Me
10.1016/j.joto.2017.06.002in 93% of cases at 18-months (Wick et al., 2017). Steroid also
appears to abate drop attacks. In a crucial retrospective study,
Liu et al. (2016) investigated whether intratympanic dexa-
methasone (delivered once a week for 4 consecutive weeks) is
effective in the treatment of drop attacks in Meniere's disease.
Remarkably, the authors showed that 6/7 patients experienced
total abolition of drop attacks after either just a single course (5
patients) or after two (1 patient). Although one patient experi-
enced no improvement, this finding is particularly important
because drop attacks can cause serious injury and the current
gold-standard treatment is aggressive intratympanic gentamicin
or vestibular nerve section.5. Conclusion
If Meniere's disease patients continue to experience attacks
of vertigo despite dietary management or oral medication,
intratympanic steroid may be used as an as-needed therapy.
With steroid, there is little risk of hearing loss, chronic
symptoms of dizziness resulting from the fixed vestibular loss
or adverse events. As many patients with Meniere's disease are
frail or experience anxiety that complicates ablative therapy,
intratympanic steroid is an excellent option. That said, clini-
cians must decide the appropriate treatment in concordance
with the patient's expectation as intratympanic steroid treat-
ment may need to be repeated periodically.Conflicts of interest
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